Protagenic Therapeutics, Inc.new (PTIX) Research & Development (2010 - 2026)
Protagenic Therapeutics, Inc.new's Research & Development came in at $26,904 for fiscal Q2 2027 (quarter ended Sep 30, 2026), down 87.7% from $218,343 a year earlier and down 75.5% from the prior quarter.
Protagenic Therapeutics, Inc.new (PTIX) Research & Development (2010 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, Protagenic Therapeutics, Inc.new reported Research & Development of $371,384, down 77.2% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $901,896, up 139.4% from FY2025.
- Research & Development carries a five-year compound annual growth rate of -4.5% (FY2021 to FY2026).
- Going back by fiscal year, Research & Development was $376,740 in FY2025, $3.84 million in FY2024 (+25.5%), $3.06 million in FY2023 (+92.8%) and $1.59 million in FY2022 (+39.8%).
- The fiscal Q2 2027 figure represents the lowest quarterly Research & Development since fiscal Q3 2015.
- Year-over-year, Research & Development has declined for three consecutive quarters.
- Business Quant data shows PTIX's Research & Development at $109,925 (Q1 2027), $80,769 (Q4 2026) and $153,786 (Q3 2026) in the three fiscal quarters before Q2 2027.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,300.96 Bn | 1,274.58 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 691.57 Bn | 611.43 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 526.86 Bn | 494.87 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 365.17 Bn | 328.11 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 314.51 Bn | 287.74 Bn | - | - |
| 6 | Astrazeneca | 288.94 Bn | 262.45 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 254.33 Bn | 205.98 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 211.53 Bn | 186.64 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 166.13 Bn | 113.48 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Protagenic Therapeutics, Inc.new | 850,797.76 | -3.51 Mn | - | 26,904.00 |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 26,904.00 |
| Jun 30, 2026 | 109,925.00 |
| Mar 31, 2026 | 80,769.00 |
| Dec 31, 2025 | 153,786.00 |
| Sep 30, 2025 | 218,343.00 |
| Jun 30, 2025 | 394,112.00 |
| Mar 31, 2025 | 880,372.00 |
| Dec 31, 2024 | 134,580.00 |
| Sep 30, 2024 | 16,964.00 |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 671,169.00 |
| Mar 31, 2023 | 348,031.00 |
| Dec 31, 2022 | 257,520.00 |
| Sep 30, 2022 | 501,366.00 |
| Jun 30, 2022 | 160,515.00 |
| Mar 31, 2022 | 669,838.00 |
| Dec 31, 2021 | 146,568.00 |
Protagenic Therapeutics, Inc.new Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=PTIX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "PTIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=PTIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();